HOOK News and Press, HOOKIPA Pharma Inc.

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collabora...

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrati...

Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20 Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc....

2024-05-24 14:26:46 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to receive $10M from Roche as FDA clears cancer trial Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earn...

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined posit...

2024-05-16 14:27:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential. ...

2024-05-09 11:55:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ: HOOK ) just reported results for the first quarter of 2024. HOOKIPA Pharma reported earnings per share of 11 cents. This was above the analyst esti...

2024-05-09 07:57:23 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to receive $10M from Roche as FDA clears cancer trial Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earn...

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) de...